Given its ability to inhibit MCT1 in tumors expressing high MCT1 levels, AZD3965 could enhance drug penetration across the BBB and modulate the tumor microenvironment, warranting further investigation in glioblastoma models (Table 3). Here, SLC16A1 is linked to neoplasm.